Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

We recently published These 10 Stocks Just Lost Their Spark. Abbott Laboratories (NYSE:ABT) is one of the worst-performing ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below ...

Fintel reports that on July 18, 2025, Jefferies upgraded their outlook for Abbott Laboratories (NYSE:ABT) from Hold to Buy.

Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...

Abbott Laboratories stock tumbled Thursday after the maker of medical devices and nutrition products narrowed its full-year ...

The healthcare-products maker trimmed and narrowed its guidance for the year while reporting strong profit and sales gains in the second quarter.